Application of Bayesian approaches in drug development: starting a virtuous cycle

Area of Science:

• Biostatistics
• Pharmaceutical Sciences
• Clinical Trial Methodology

Background:

• Frequentist statistical methods, including null hypothesis significance testing and p-values, are standard in pharmaceutical evaluation.
• The clinical drug development process generates accumulating data, making it suitable for Bayesian approaches.

Purpose of the Study:

• To highlight the value of Bayesian methods in drug development.
• To discuss barriers hindering the routine application of Bayesian approaches.
• To recommend strategies for increased adoption of Bayesian methods.

Main Methods:

• Review of current practices in pharmaceutical statistics.
• Discussion of Bayesian methodology's potential in clinical trial design and analysis.
• Identification of challenges and facilitators for Bayesian method implementation.

Main Results:

• Bayesian approaches can reduce drug development time and costs.
• These methods can minimize patient exposure to ineffective or unsafe treatments.
• Bayesian methods remain underused despite methodological advances and data availability.

Conclusions:

• Bayesian methods offer significant advantages for drug development and regulatory review.
• Addressing barriers is crucial for the routine implementation of Bayesian statistical approaches.
• Increased stakeholder engagement is needed to leverage existing data effectively through Bayesian analysis.